Announcements
OBI-822 “Cancer Immunotherapy by Immune Activation or Immune Modulation via Globo Series Antigens“ was granted by USPTO
1.Date of occurrence of the event:2022/10/13 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence:OBI Pharma Inc. …
Announcement on behalf of AP Biosciences of the resignation of its institutional director
1.Date of occurrence of the change: 2022/10/6 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): institutional director 3.Title and name of …
OBI PHARMA INC. to attend investor conference hosted by MASTERLINK SECURITIES
1.Date of institutional investor conference:2022/10/12 2.Time of institutional investor conference:14:30:00 NST 3.Location of institutional investor conference:Taipei New Horizon (Address: 6F., No. 88, Yanchang Rd., Xinyi Dist., Taipei City 110, Taiwan) …
Announcement of AP Biosciences’ full receipt of cash capital increase in 2022 and the reference date of capital increase
1.Date of occurrence of the event:2022/10/04 2.Company name:AP Biosciences Inc. (hereinafter referred to as APBio) 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries 4.Reciprocal shareholding ratios:Not applicable 5.Cause …
Announcement of the expiration of AP Biosciences’ 2022 cash capital increase call period
1.Date of occurrence of the event:2022/10/03 2.Company name:AP Biosciences Inc. (hereinafter referred to as APBio) 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries 4.Reciprocal shareholding ratios:Not applicable 5.Cause …
Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to TFDA
1.Date of occurrence of the event:2022/09/12 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences (hereinafter referred to as APBio). …
Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by US FDA
1.Date of occurrence of the event:2022/09/10 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences (hereinafter referred to as APBio). …
Announcement on behalf of AP Biosciences that preemptive rights forfeited by all directors are over 50% and made available to specific persons
1.Date of occurrence of the event:2022/08/31 2.Reason for the forfeiture of subscription rights by the directors nd supervisors: In accordance with related laws and regulations, to coordinate with AP Bioscineces’ …
Announcement on behalf of AP Biosciences’ call period of 2022 cash capital increase
1.Date of occurrence of the event:2022/08/31 2.Company name:AP Biosciences Inc. (Hereinafter referred to as APBio) 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries 4.Reciprocal shareholding ratios:Not applicable. 5.Cause …
Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA
1.Date of occurrence of the event:2022/08/12 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences (hereinafter referred to as APBio). …